A Study of LY3457263 in Obese Participants

NCT05582096 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight
Obesity

Interventions

DRUG: LY3457263
DRUG: Tirzepatide
DRUG: Placebo

Sponsor

Eli Lilly and Company